Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development

Headache

Volumn 53, Issue 8, 2013, Pages 1230-1244

  Bigal, Marcelo E ^a   Walter, Sarah ^a   Rapoport, Alan M ^b  

^a TEVA PHARMACEUTICALS   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibodies; calcitonin gene related peptide; chronic migraine; migraine

Indexed keywords

ALD 403; AMG 334; ANTIMIGRAINE AGENT; BI 44370A; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; ELETRIPTAN; GLYCERYL TRINITRATE; LBR 101; LY 2951742; MK 3207; MONOCLONAL ANTIBODY; OLCEGEPANT; PLACEBO; RIZATRIPTAN; TELCAGEPANT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; CARDIOVASCULAR FUNCTION; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG HALF LIFE; EPISODIC MIGRAINE; EXERCISE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOMEOSTASIS; HUMAN; MIGRAINE; NERVE CELL PLASTICITY; NOCICEPTION; PARESTHESIA; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SINGLE DRUG DOSE; STABLE ANGINA PECTORIS; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSFORMED MIGRAINE; TREADMILL EXERCISE; VASODILATATION;

ANTIBODIES; CALCITONIN GENE-RELATED PEPTIDE; CHRONIC MIGRAINE; MIGRAINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CALCITONIN GENE-RELATED PEPTIDE; CLINICAL TRIALS AS TOPIC; COMPREHENSION; HUMANS; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 84884151958     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12179     Document Type: Article

References (115)

1. Terenghi G, Polak JM, Ghatei MA, et al. Distribution and origin of calcitonin gene-related peptide (CGRP) immunoreactivity in the sensory innervation of the mammalian eye. J Comp Neurol. 1985; 233: 506-516.
2. Alevizaki M, Shiraishi A, Rassool FV, Ferrier GJ, MacIntyre I, Legon S,. The calcitonin-like sequence of the beta CGRP gene. FEBS Lett. 1986; 206: 47-52.
3. Raddant AC, Russo AF,. Calcitonin gene-related peptide in migraine: Intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011; 13: e36.
4. Noguchi K, Senba E, Morita Y, Sato M, Tohyama M,. Alpha-CGRP and beta-CGRP mRNAs are differentially regulated in the rat spinal cord and dorsal root ganglion. Brain Res Mol Brain Res. 1990; 7: 299-304.
5. Tippins JR, Di Marzo V, Panico M, Morris HR, MacIntyre I,. Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). Biochem Biophys Res Commun. 1986; 134: 1306-1311.
6. Juaneda C, Dumont Y, Quirion R,. The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci. 2000; 21: 432-438.
7. Recober A, Russo AF,. Calcitonin gene-related peptide: An update on the biology. Curr Opin Neurol. 2009; 22: 241-246.
8. Emeson RB, Hedjran F, Yeakley JM, Guise JW, Rosenfeld MG,. Alternative production of calcitonin and CGRP mRNA is regulated at the calcitonin-specific splice acceptor. Nature. 1989; 341: 76-80.
9. van Rossum D, Hanisch UK, Quirion R,. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997; 21: 649-678.
10. Edvinsson L, Goadsby PJ,. Extracerebral manifestations in migraine. A peptidergic involvement? J Intern Med. 1990; 228: 299-304.
11. Goadsby PJ, Edvinsson L, Ekman R,. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990; 28: 183-187.
12. Peroutka SJ,. Clinical trials update-2012: Year in review. Headache. 2013; 53: 177-180.
13. Silberstein SD,. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013; 93: 78-85.
14. Lundberg JM, Franco-Cereceda A, Hua X, Hokfelt T, Fischer JA,. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol. 1985; 108: 315-319.
15. Lundberg JM, Franco-Cereceda A, Alving K, Delay-Goyet P, Lou YP,. Release of calcitonin gene-related peptide from sensory neurons. Ann N Y Acad Sci. 1992; 657: 187-193.
16. Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988; 25: 195-205.
17. Feuerstein G, Willette R, Aiyar N,. Clinical perspectives of calcitonin gene related peptide pharmacology. Can J Physiol Pharmacol. 1995; 73: 1070-1074.
18. Poyner D,. Pharmacology of receptors for calcitonin gene-related peptide and amylin. Trends Pharmacol Sci. 1995; 16: 424-428.
19. Toda M, Suzuki T, Hosono K, et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci U S A. 2008; 105: 13550-13555.
20. Allen DM, Chen LE, Seaber AV, Urbaniak JR,. Calcitonin gene-related peptide and reperfusion injury. J Orthop Res. 1997; 15: 243-248.
21. Kallner G, Gonon A, Franco-Cereceda A,. Calcitonin gene-related peptide in myocardial ischaemia and reperfusion in the pig. Cardiovasc Res. 1998; 38: 493-499.
22. Lynch JJ Jr, Detwiler TJ, Kane SA, Regan CP,. Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats. J Cardiovasc Pharmacol. 2010; 56: 518-525.
23. Supowit SC, Ethridge RT, Zhao H, Katki KA, Dipette DJ,. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol. 2005; 289: H1169-H1175.
24. Brain SD, Grant AD,. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004; 84: 903-934.
25. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I,. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985; 313: 54-56.
26. Sinclair SR, Kane SA, Van der Schueren BJ, et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol. 2010; 69: 15-22.
27. Goadsby PJ, Edvinsson L, Ekman R,. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988; 23: 193-196.
28. Denekas T, Troltzsch M, Vater A, Klussmann S, Messlinger K,. Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol. 2006; 148: 536-543.
29. Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G,. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005; 25: 179-183.
30. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: Strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003; 106: 461-470.
31. Hansen JM, Hauge AW, Olesen J, Ashina M,. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010; 30: 1179-1186.
32. Ashina M, Bendtsen L, Jensen R, Schifter S, Jansen-Olesen I, Olesen J,. Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology. 2000; 55: 1335-1340.
33. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J,. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61.
34. Zhang JF, Liu J, Liu XZ, Sheng SL, Zhang WJ, Chen YJ,. The effect of calcitonin gene-related peptide on arrhythmia caused by adenosine diphosphate and desacetyldigilanide-C in rats. Int J Cardiol. 1991; 33: 43-46.
35. Atkins BZ, Silvestry SC, Samy RN, Shah AS, Sabiston DC Jr, Glower DD,. Calcitonin gene-related peptide enhances the recovery of contractile function in stunned myocardium. J Thorac Cardiovasc Surg. 2000; 119: 1246-1254.
36. Zhou ZH, Peng J, Ye F, Li NS, Deng HW, Li YJ,. Delayed cardioprotection induced by nitroglycerin is mediated by alpha-calcitonin gene-related peptide. Naunyn Schmiedebergs Arch Pharmacol. 2002; 365: 253-259.
37. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010; 334: 746-752.
38. Lynch JJ, Shen YT, Pittman TJ, et al. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009; 623: 96-102.
39. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147.
40. Verheggen R, Bumann K, Kaumann AJ,. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: Comparison with CGRP(8-37). Br J Pharmacol. 2002; 136: 120-126.
41. Van der Schueren BJ, Blanchard R, Murphy MG, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011; 71: 708-717.
42. Chaitman BR, Ho AP, Behm MO, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012; 91: 459-466.
43. Conolan S, Taylor DA,. Antagonism by some ergot derivatives of 5-HT-induced vasoconstriction. Eur J Pharmacol. 1986; 123: 299-302.
44. Maassen VanDenBrink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR,. Augmented contraction of the human isolated coronary artery by sumatriptan: A possible role for endogenous thromboxane. Br J Pharmacol. 1996; 119: 855-862.
45. Longmore J, Hargreaves RJ, Boulanger CM, et al. Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: Outcome of two independent studies using different experimental protocols. Funct Neurol. 1997; 12: 3-9.
46. Li L, Wang X, Yu LC,. Involvement of opioid receptors in the CGRP-induced antinociception in the nucleus accumbens of rats. Brain Res. 2010; 1353: 53-59.
47. Yu LC, Weng XH, Wang JW, Lundeberg T,. Involvement of calcitonin gene-related peptide and its receptor in anti-nociception in the periaqueductal grey of rats. Neurosci Lett. 2003; 349: 1-4.
48. Benarroch EE,. CGRP: Sensory neuropeptide with multiple neurologic implications. Neurology. 2011; 77: 281-287.
49. Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF,. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can J Physiol Pharmacol. 1995; 73: 1020-1024.
50. Unger JW, Lange W,. Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord. J Chem Neuroanat. 1991; 4: 299-309.
51. Lennerz JK, Ruhle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008; 507: 1277-1299.
52. Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ,. CGRP and NO in the trigeminal system: Mechanisms and role in headache generation. Headache. 2012; 52: 1411-1427.
53. Eftekhari S, Edvinsson L,. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010; 3: 369-378.
54. Vause CV, Durham PL,. Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: Findings from array analysis. Neurosci Lett. 2010; 473: 163-167.
55. Ceruti S, Villa G, Fumagalli M, et al. Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: Implications for basic mechanisms of migraine pain. J Neurosci. 2011; 31: 3638-3649.
56. Russo AF, Kuburas A, Kaiser EA, Raddant AC, Recober A,. A potential preclinical migraine model: CGRP-sensitized mice. Mol Cell Pharmacol. 2009; 1: 264-270.
57. Markowitz S, Saito K, Buzzi MG, Moskowitz MA,. The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells. Brain Res. 1989; 477: 157-165.
58. Eftekhari S, Edvinsson L,. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci. 2011; 12: 112.
59. Mathew R, Andreou AP, Chami L, et al. Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. Cephalalgia. 2011; 31: 1368-1380.
60. Goadsby PJ,. Neurovascular headache and a midbrain vascular malformation: Evidence for a role of the brainstem in chronic migraine. Cephalalgia. 2002; 22: 107-111.
61. Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ,. Brainstem activation specific to migraine headache. Lancet. 2001; 357: 1016-1017.
62. Moskowitz MA,. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43 (6 Suppl. 3): S16-S20.
63. Williamson DJ, Hargreaves RJ,. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001; 53: 167-178.
64. Sun RQ, Lawand NB, Willis WD,. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. Pain. 2003; 104: 201-208.
65. Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ,. Migraine in the triptan era: Lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009; 49 (Suppl. 1): S21-S33.
66. Ho TW, Edvinsson L, Goadsby PJ,. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6: 573-582.
67. Morara S, Rosina A, Provini L, Forloni G, Caretti A, Wimalawansa SJ,. Calcitonin gene-related peptide receptor expression in the neurons and glia of developing rat cerebellum: An autoradiographic and immunohistochemical analysis. Neuroscience. 2000; 100: 381-391.
68. Pagani F, Guidobono F, Netti C, Re F, Pecile A,. Age-related increase in CGRP binding site densities in rat cerebellum. Pharmacol Res. 1989; 21 (Suppl. 1): 105-106.
69. Noseda R, Burstein R,. Advances in understanding the mechanisms of migraine-type photophobia. Curr Opin Neurol. 2011; 24: 197-202.
70. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF,. Role of calcitonin gene-related peptide in light-aversive behavior: Implications for migraine. J Neurosci. 2009; 29: 8798-8804.
71. Seybold VS, Galeazza MT, Garry MG, Hargreaves KM,. Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Can J Physiol Pharmacol. 1995; 73: 1007-1014.
72. Bird GC, Han JS, Fu Y, Adwanikar H, Willis WD, Neugebauer V,. Pain-related synaptic plasticity in spinal dorsal horn neurons: Role of CGRP. Mol Pain. 2006; 2: 31.
73. Galeazza MT, Garry MG, Yost HJ, Strait KA, Hargreaves KM, Seybold VS,. Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience. 1995; 66: 443-458.
74. Moulton EA, Schmahmann JD, Becerra L, Borsook D,. The cerebellum and pain: Passive integrator or active participator? Brain Res Rev. 2010; 65: 14-27.
75. Kruit MC, Launer LJ, Ferrari MD, van Buchem MA,. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain. 2005; 128 (Pt 9): 2068-2077.
76. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004; 291: 427-434.
77. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110.
78. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312.
79. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
80. Hoffmann J, Goadsby PJ,. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr Treat Options Neurol. 2012; 14: 50-59.
81. Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010; 333: 152-160.
82. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722.
83. Pettypiece S,. Merck halts testing of migraine drug on liver safety (Update2). 2009. Available at: http://www.bloomberg.com/apps/news?pid= newsarchive&sid=aKxzpNBZ2cbA (accessed April 4, 2013).
84. Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J,. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia. 2011; 31: 573-584.
85. Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011; 51: 73-84.
86. Health NIo,. Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition. 2013. Available at: http://clinicaltrial.gov/ct2/show/NCT01445067?term=CGRP&recr=Open&rank= 4 (accessed April 5, 2013).
87. A dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006 AM1). 2013. Available at: http://clinicaltrial.gov/ct2/show/ NCT01613248?term=MK1602&rank=2 (accessed April 10, 2013).
88. Miller RA, Maloney DG, Warnke R, Levy R,. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982; 306: 517-522.
89. Mould DR, Sweeney KR,. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007; 10: 84-96.
90. Harding FA, Stickler MM, Razo J, DuBridge RB,. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. Mabs. 2010; 2: 256-265.
91. Tsurushita N, Hinton PR, Kumar S,. Design of humanized antibodies: From anti-Tac to Zenapax. Methods. 2005; 36: 69-83.
92. Hwang WY, Foote J,. Immunogenicity of engineered antibodies. Methods. 2005; 36: 3-10.
93. Wu H, Dall'Acqua WF,. Humanized antibodies and their applications. Methods. 2005; 36: 1-2.
94. Services USDoHaH, Administration FaD, (CDER) CfDEaR, (CBER) CfBEaR. Guidance for industry. M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 1994. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf (accessed April 24, 2013).
95. Baumann A,. Early development of therapeutic biologics-pharmacokinetics. Curr Drug Metab. 2006; 7: 15-21.
96. Bussiere JL,. General toxicity testing and immunotoxicity testing for biopharmaceuticals. In:, Cavagnaro JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. New York: Wiley; 2008: 125-155.
97. Services UDoHaH, Administration FaD, (CDER) CfDEaR, (CBER) CfBEaR. Guidance for industry, S6 Preclinical safety evaluation of biotechnology-derived pharmaceuticals, 1997. Available at: http://www.fda.gov/downloads/ regulatoryinformation/guidances/ucm129171.pdf (accessed April 20, 2013).
98. Vargas HM, Bass AS, Breidenbach A, et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods. 2008; 58: 72-76.
99. clinicaltrial.gov. A study of LY2951742 in healthy volunteers. 2013. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01337596?term= LY2951742&rank=1 (accessed April 10, 2013).
100. A study of LY2951742 in patients with migraine. 2013. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01625988?term=LY2951742&rank=2 (accessed April 10, 2013).
101. Safety, efficacy and pharmacokinetics of ALD403. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01772524?term=ald403&rank=2 (accessed April 10, 2013).
102. Amgen-science-pipeline. 2013. Available at: http://www.amgen.com/science/ pipe.html (accessed April 10, 2013).
103. Ascending single doses of AMG 334 in healthy subjects and migraine patients. 2013. Available at: http://clinicaltrial.gov/ct2/show/NCT01688739? term=AMG334&rank=1 (accessed April 10, 2013).
104. Ascending multiple-doses of AMG 334 in healthy subjects and in migraine patients. 2013. Available at: http://clinicaltrial.gov/ct2/show/NCT01723514? term=AMG334&rank=2 (accessed April 10, 2013).
105. Phase 1 studies of LBR-101 (PF-04427429) listed at clinicaltrials.gov. 2013. Available at: http://clinicaltrials.gov/ct2/results?term=PF- 04427429&Search=Search (accessed April 10, 2013).
106. Bigal ME, Buse DC, Chen YT, et al. Rates and predictors of starting a triptan: Results from the american migraine prevalence and prevention study. Headache. 2010; 50: 1440-1448.
107. Bigal ME, Borucho S, Serrano D, Lipton RB,. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia. 2009; 29: 891-897.
108. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB,. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
109. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB,. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008; 48: 1157-1168.
110. Bigal ME, Kurth T, Santanello N, et al. Migraine and cardiovascular disease: A population-based study. Neurology. 2010; 74: 628-635.
111. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
112. Silberstein SD, Dodick D, Kesslick J,. Removing barriers to appropriate migraine treatment: Formulary limitations and triptan package size. Headache. 2005; 45: 1250-1254.
113. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011; 77: 1465-1472.
114. Evans RW,. A rational approach to the management of chronic migraine. Headache. 2013; 53: 168-176.
115. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.